The VGLL4–TEAD4/CEBPA–PDK4 axis as a key driver of MAFLD is unveiled and its pharmacological blockade alleviates hepatic steatosis in model mice and represents a viable strategy to halt MAFLD progression.
Abstract
MAFLD is a global epidemic with a limited number of approved targeted therapies, underscoring the urgent need to define its underlying regulatory mechanisms. Here, we identify VGLL4 as a positive regulator of MAFLD progression. Hepatocyte-specific overexpression of Vgll4 induces hepatic steatosis, insulin resistance, and inflammation, whereas its knockout protects mice from HFD-induced metabolic dysfunction. Mechanistically, VGLL4 strengthens the interaction between TEAD4 and CEBPA and promotes the cooperative activation of Pdk4 expression. Functional studies identify PDK4 as a downstream effector, as its knockdown alleviates VGLL4-exacerbated hepatosteatosis in vivo. YAP attenuates this regulatory mechanism and suppresses Pdk4 transcription during hepatic steatosis. Notably, administration of Super-TDU, a peptide that disrupts the VGLL4–TEADs interaction, significantly alleviates hepatic steatosis in both HFD-fed mice and Vgll4-overexpressing mice. Our findings unveil the VGLL4–TEAD4/CEBPA–PDK4 axis as a key driver of MAFLD and demonstrate that its pharmacological blockade alleviates hepatic steatosis in model mice. Hepatic VGLL4 promotes MAFLD by enhancing steatosis and impairing insulin signaling. Mechanistically, VGLL4 promotes TEAD4/CEBPA-dependent PDK4 transcription, while disrupting VGLL4/TEAD4 binding alleviates fatty liver phenotypes. VGLL4 acts as a hepatocyte-specific driver of MAFLD progression. VGLL4 enhances TEAD4-CEBPA cooperation to activate Pdk4 transcription and promote hepatic lipid accumulation. Targeting the VGLL4/TEADs complex with Super-TDU represents a viable strategy to halt MAFLD progression. VGLL4 acts as a hepatocyte-specific driver of MAFLD progression. VGLL4 enhances TEAD4-CEBPA cooperation to activate Pdk4 transcription and promote hepatic lipid accumulation. Targeting the VGLL4/TEADs complex with Super-TDU represents a viable strategy to halt MAFLD progression. Hepatic VGLL4 promotes MAFLD by enhancing steatosis and impairing insulin signaling. Mechanistically, VGLL4 promotes TEAD4/CEBPA-dependent PDK4 transcription, while disrupting VGLL4/TEAD4 binding alleviates fatty liver phenotypes.
BACKGROUND
Programmed cell death factor 4 (PDCD4) has been implicated in various metabolic disorders. However, its role and underlying mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) have not been fully elucidated.
PURPOSE
This study aimed to define the role of PDCD4 in hepatic steatosi...
Xiao-Na Cheng, Kai-Kai Lu, Lu-Yun Yang et al.· Phytomedicine· 0 citations
Emerging evidence links circadian disruption to metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying mechanisms remain elusive. NPAS2, a core circadian regulator, has an undefined role in the pathogenesis of MASLD and its progression to hepatocellular carcinoma (HCC). This study aime...
Jiao Mu, Jia-Li Ye, Jia-Hao Zhang et al.· Cell Death & Disease· 0 citations
The results establish PDIA5 as a critical molecular checkpoint linking hepatic lipid overload to glucose dysregulation, and highlight it as a potential therapeutic target for type 2 diabetes.
Jin-Tao Wan, Ming-Liang Zhang, Teng Ma et al.· Diabetologia· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global metabolic epidemic with limited therapeutic options. Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) has been implicated in glucose metabolism, but its functional role and regulatory mechanisms in MASLD remain unknown. In this study, we establish...
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global health burden, yet the regulatory nodes linking hepatic immune dysregulation to metabolic perturbations remain incompletely understood.
METHODS
We integrated bulk and single-cell RNA sequencing (scRNA-seq) to identify core...
Yan Wang, Shuang-Shuang Lu· Frontiers in Bioscience· 0 citations
Disordered lipid metabolism and inflammation, the hallmark features of metabolic dysfunction-associated steatohepatitis (MASH), present a significant therapeutic challenge even in the absence of obesity, making the discovery of novel pathogenic mechanisms and therapies imperative. Although Celastrol (Cel) markedly amel...
Hu Hua, Wen-Ping Zhu, Le-Hang Sun et al.· Biochimica et Biophysica Act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.